SAB-185, a human IgG1 (polyclonal) antibody therapeutic candidate, demonstrated benefit in sustained symptom resolution in patients with Omicron variants of...
JERUSALEM, April 26, 2023 (GLOBE NEWSWIRE) -- Entera Bio Ltd. (NASDAQ: ENTX) (“Entera” or the “Company”) a leader in the...
Fremont, CA, April 26, 2023 (GLOBE NEWSWIRE) -- via NewMediaWire – ABVC BioPharma, Inc. (NASDAQ: ABVC), a clinical stage biopharmaceutical...
BERKELEY HEIGHTS, N.J., April 26, 2023 (GLOBE NEWSWIRE) -- CorMedix Inc. (Nasdaq: CRMD), a biopharmaceutical company focused on developing and...
CAMBRIDGE, Mass., April 26, 2023 (GLOBE NEWSWIRE) -- Spero Therapeutics, Inc. (Nasdaq: SPRO) (Spero), a multi-asset clinical-stage biopharmaceutical company, focused on...
BOSTON, April 26, 2023 (GLOBE NEWSWIRE) -- X4 Pharmaceuticals, Inc. (Nasdaq: XFOR), a leader in the discovery and development of...
WARREN, N.J., April 26, 2023 (GLOBE NEWSWIRE) -- Aquestive Therapeutics, Inc. (NASDAQ: AQST), a pharmaceutical company advancing medicines to solve...
New Analysis Indicates No Drug-Drug Interactions (DDIs) of Clinical Concern are Predicted When Recommended Doses of Trudhesa and Gepants are...
ROCKAWAY, N.J., April 26, 2023 (GLOBE NEWSWIRE) -- electroCore, Inc. (Nasdaq: ECOR), a commercial-stage bioelectronic medicine and wellness company, today announced...
• Mavacamten met the primary endpoint for the treatment of Chinese patients with symptomatic obstructive hypertrophic cardiomyopathy • Mavacamten demonstrated a...
Submits Provisional Patent Application entitled “Nanoparticles Comprising Payloads and Their In Vivo Delivery.”BOSTON, April 26, 2023 (GLOBE NEWSWIRE) -- TransCode...
Global Cross-Industry Collaboration Continues Sharing Outputs to Improve Research Access SAN DIEGO, April 25, 2023 (GLOBE NEWSWIRE) -- The Decentralized...
BEFORE Unretouched photos, taken in standard lighting. Results may vary. AFTER Unretouched photos, taken in standard lighting. Results may vary....
Providence, RI, April 25, 2023 (GLOBE NEWSWIRE) -- Ocean Biomedical, Inc. (NASDAQ: OCEA), a biopharma company working to accelerate the development...
Topline data anticipated in mid-2024 SIGNAL-AD builds on promising data from the Phase 2 SIGNAL Study in Huntington’s Disease ROCHESTER,...
CINCINNATI, April 25, 2023 (GLOBE NEWSWIRE) -- Blue Water Biotech, Inc. (“Blue Water” or the “Company”), a biotechnology company spanning...
Promising preliminary antitumor activity with the combination demonstrated in heavily pretreated patients 47% ORR, 5.5 months mPFS observed with preferred...
BOSTON, April 25, 2023 (GLOBE NEWSWIRE) -- Cue Biopharma, Inc. (Nasdaq: CUE), a clinical-stage biopharmaceutical company developing a novel class of...
PDUFA Date of September 28, 2023 Set for Nyxol® in its First Indication, Reversal of Pharmacologically-induced Mydriasis (RM); $10 Million...
PharmAla will be the initial supplier for clinical materials in a series of Psychedelic therapy clinics planned for opening by...